Brief: Strides Pharma Science Unit Strides Gets A$94 Million As Deferred Consideration For Sale Of Australian Operations In 2019
22/12/2022 05:51
Dec 22 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* UNIT STRIDES PHARMA GLOBAL GETS A$94 MILLION AS DEFERRED
CONSIDERATION FOR SALE OF AUSTRALIAN OPERATIONS IN 2019
* PROCEEDS WILL BE UTILIZED FOR DELEVERAGING BALANCE SHEET
Source text for Eikon: ID:nNSEb2l0zS
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees